BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weston-Bell NJ, Hendriks D, Sugiyarto G, Bos NA, Kluin-Nelemans HC, Forconi F, Sahota SS. Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia 2013;27:241-5. [PMID: 22705994 DOI: 10.1038/leu.2012.163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Maevis V, Mey U, Schmidt-Wolf G, Schmidt-Wolf IG. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 2014;4:e184. [PMID: 24531447 DOI: 10.1038/bcj.2014.3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
2 Li YZ, Wang YY, Huang L, Zhao YY, Chen LH, Zhang C. Annexin A Protein Family in Atherosclerosis. Clin Chim Acta 2022:S0009-8981(22)01143-3. [PMID: 35562096 DOI: 10.1016/j.cca.2022.05.009] [Reference Citation Analysis]
3 Arribas AJ, Rinaldi A, Chiodin G, Kwee I, Mensah AA, Cascione L, Rossi D, Kanduri M, Rosenquist R, Zucca E, Johnson PW, Gaidano G, Oakes CC, Bertoni F, Forconi F. Genome-wide promoter methylation of hairy cell leukemia. Blood Adv 2019;3:384-96. [PMID: 30723113 DOI: 10.1182/bloodadvances.2018024059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Tiacci E, Pettirossi V, Schiavoni G, Falini B. Genomics of Hairy Cell Leukemia. J Clin Oncol 2017;35:1002-10. [PMID: 28297625 DOI: 10.1200/JCO.2016.71.1556] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 6.6] [Reference Citation Analysis]
5 Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019;37 Suppl 1:30-7. [PMID: 31187521 DOI: 10.1002/hon.2594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
6 Paillassa J, Safa F, Troussard X. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. Therapeutic Advances in Hematology 2022;13:204062072210908. [DOI: 10.1177/20406207221090886] [Reference Citation Analysis]
7 Weston-Bell NJ, Tapper W, Gibson J, Bryant D, Moreno Y, John M, Ennis S, Kluin-Nelemans HC, Collins AR, Sahota SS. Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. PLoS One 2016;11:e0149162. [PMID: 26871591 DOI: 10.1371/journal.pone.0149162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 Lee WY. "Hairiness" is a Facsimile of Reorganized Cytoskeletons: A Cytopathic Effect of Coxiella burnetii. Yonsei Med J 2019;60:890-7. [PMID: 31538423 DOI: 10.3349/ymj.2019.60.10.890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Arons E, Zhou H, Sokolsky M, Gorelik D, Potocka K, Davies S, Fykes E, Still K, Edelman DC, Wang Y, Meltzer PS, Raffeld M, Wiestner A, Xi L, Wang HW, Stetler-Stevenson M, Yuan C, Kreitman RJ. Expression of the muscle-associated gene MYF6 in hairy cell leukemia. PLoS One 2020;15:e0227586. [PMID: 32040482 DOI: 10.1371/journal.pone.0227586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Weston-Bell NJ, Forconi F, Kluin-Nelemans HC, Sahota SS. Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes. PLoS One 2014;9:e86556. [PMID: 24497953 DOI: 10.1371/journal.pone.0086556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Oscier D, Stamatopoulos K, Mirandari A, Strefford J. The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma. Cancers 2022;14:697. [DOI: 10.3390/cancers14030697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vereertbrugghen A, Colado A, Gargiulo E, Bezares RF, Fernández Grecco H, Cordini G, Custidiano MDR, François JH, Berchem G, Borge M, Paggetti J, Moussay E, Gamberale R, Giordano M, Morande PE. In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Front Oncol 2021;11:598319. [PMID: 34381700 DOI: 10.3389/fonc.2021.598319] [Reference Citation Analysis]
13 Niu Y, Yang X, Chen Y, Jin X, Xie Y, Tang Y, Li L, Liu S, Guo Y, Li X, Duan L, Wang H. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia. Clin Transl Oncol 2019;21:1186-96. [PMID: 30694461 DOI: 10.1007/s12094-019-02045-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood 2016;128:1918-27. [DOI: 10.1182/blood-2016-07-418434] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
15 Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 2014;166:177-88. [PMID: 24697238 DOI: 10.1111/bjh.12867] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
16 Nagel S, Ehrentraut S, Meyer C, Kaufmann M, Drexler HG, Macleod RA. NFkB is activated by multiple mechanisms in hairy cell leukemia: NFkB IS Activated by Multiple Mechanisms. Genes Chromosomes Cancer 2015;54:418-32. [DOI: 10.1002/gcc.22253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
17 Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P. Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Sci Rep 2016;6:21252. [PMID: 26893254 DOI: 10.1038/srep21252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Sivina M, Burger JA. The importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol 2015;28:208-16. [PMID: 26614899 DOI: 10.1016/j.beha.2015.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Machnicki MM, Stoklosa T. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53:77-83. [PMID: 24495477 DOI: 10.1016/j.bcmd.2014.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
20 Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 2015;125:1207-16. [PMID: 25480661 DOI: 10.1182/blood-2014-10-603100] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]